Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Beat the Market on Monday

By Eric Volkman – Aug 9, 2021 at 6:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another analyst ups his recommendation on the stock.

What happened

Editas Medicine (EDIT -2.52%) got a spoonful of good medicine on Monday that gave its shares a healthy lift; ultimately, the stock closed the day more than 4.4% higher.

So what

That boost was delivered by Truist Securities biotech analyst Joon Lee. On Monday morning, he upgraded his recommendation on Editas stock to buy from the previous hold. He also substantially increased his price target from $45 per share to $80.

Three strands of DNA.

Image source: Getty Images.

Lee's new bullishness on the company, which utilizes gene-editing technology to develop medications, is due to several positive factors. First, he believes Editas's leading pipeline drug EDIT-101 (which is aimed at treating Leber congenital amaurosis, an eye disorder) "could show signs of efficacy" when the company publishes the first data from an early-phase clinical trial. This is slated to occur in September.

Second, the prognosticator is also enthusiastic about gene-editing intellectual property that Editas licenses, which has recently been the subject of a legal dispute that is lately tipping in favor of licenser the Broad Institute. Finally, in his research note, Lee touted the company's "scarcity value as a relatively unencumbered CRISPR-Cas platform company making [it] attractive as a potential partner or a target."

Now what

The Truist Securities analyst isn't the only Editas observer entering the bull pen for the stock. Last week, Evercore ISI's Liisa Bayko upped her recommendation and price target on the shares even more drastically. She flipped the former from underperform (i.e., sell) to outperform (buy), tripling the latter from $20 per share to $60.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine Stock Quote
Editas Medicine
EDIT
$9.68 (-2.52%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.